ライフサイエンスコーパス: platinum

1 success is to reduce the required amount of platinum.

2 r OVCAs that acquire resistance to PARPi and platinum.

3 ing antiferromagnet manganese difluoride and platinum.

4 o 3.2] increase) and placebo plus pemetrexed-platinum (-2.6 points [-5.8 to 0.5] decrease; between-gr

5 increase) than with placebo plus pemetrexed-platinum (-4.0 points [-7.7 to -0.3] decrease; between-g

6 ight into the cellular mechanism of a potent platinum-acridine anticancer agent (compound 1), a corre

7 study was performed for a set of rigidified platinum-acridine anticancer agents containing linkers d

8 target tumors that are likely to respond to platinum-acridines.

9 for both neurotoxicity and formation of DNA-platinum adduct formation in neurons but not in cancer c

10 hough it is postulated that formation of DNA-platinum adducts is responsible for both its cytotoxicit

11 Platinum agents are recommended versus taxanes to treat

12 ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recomb

13 No platinum allergy occurred.

14 l carcinoma who were previously treated with platinum and a checkpoint inhibitor therapy.

15 489 simultaneous measurements from Dexcom G4 Platinum and Abbott Freestyle Libre Pro CGMs during 28 i

16 num particles on the binder, which separates platinum and acid sites at the nanoscale, leads to a hig

17 survival are observed in clinically relevant platinum and acquired PARPi-resistant patient-derived xe

18 ntial lines of chemotherapy, starting with a platinum and fluoropyrimidine doublet in the first line;

19 involves reductive deposition of rhodium or platinum and oxidation of Fe(2+) from magnetite (Fe(3)O(

20 These data indicate the utility of combining platinum and PARP inhibitors in this patient population.

21 are sensitive to DNA-damaging agents such as platinum and PARP inhibitors.

22 kers, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially

23 ed oriented attachment of ~3-nanometer gold, platinum, and palladium nanoparticles.

24 nd stratified by PD-L1 expression, choice of platinum, and smoking status.

25 reached) with pembrolizumab plus pemetrexed-platinum, and was 7.0 months (4.8 months to not reached)

26 n of hydrogen currently relies on the use of platinum as a catalyst-which is scarce and expensive-and

27 support use of pembrolizumab plus pemetrexed-platinum as first-line therapy for patients with metasta

28 ure meltglass, melted microspherules, and/or platinum at other YDB sites on four continents.

29 We report the distribution of platinum at the cellular level in non-small cell lung ca

30 ce of senescent DRG neuronal cells following platinum-based cancer treatment might be an effective th

31 2 activation-mediated neuroprotection during platinum-based cancer treatment.

32 -OSO(3)H, EBS), whereas for state-of-the-art platinum-based catalysts ethionic acid (HO(3)S-CH(2)-CH(

33 esistance of CSCs to cisplatin, a prototypic platinum-based chemotherapeutic agent.

34 Oxaliplatin, a platinum-based chemotherapeutic drug, which is used as f

35 Platinum-based chemotherapies, including oxaliplatin, ar

36 ndomly assigned to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab mono

37 zumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C).

38 gression after at least one previous line of platinum-based chemotherapy (platinum-refractory).

39 me studies suggest that prior treatment with platinum-based chemotherapy affects CTGCT risk, a relati

40 re heavily pretreated, with 96% having prior platinum-based chemotherapy and 29% receiving >= 3 lines

41 utaminolysis, are intrinsically resistant to platinum-based chemotherapy and are enriched with intrac

42 nd cancer stem cells (CSCs) are resistant to platinum-based chemotherapy and drive tumor progression.

43 ving at least stable disease with first-line platinum-based chemotherapy and prolongs progression-fre

44 tients with PMNs are frequently resistant to platinum-based chemotherapy and provide TP53 mutations a

45 results support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line tr

46 Addition of atezolizumab to platinum-based chemotherapy as first-line treatment prol

47 recurrent measurable LGSOC after >= 1 prior platinum-based chemotherapy but <= 3 prior chemotherapy

48 alyzed the association between the number of platinum-based chemotherapy cycles and CTGCT risk.

49 Platinum-based chemotherapy for first-line treatment of

50 to 35 cycles or the investigator's choice of platinum-based chemotherapy for four to six cycles.

51 resses senescence-associated CSCs induced by platinum-based chemotherapy in EOC.

52 tinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic uro

53 loss confers sensitivity to irradiation and platinum-based chemotherapy in pancreatic cancer.

54 ort the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable

55 ial aimed to assess the efficacy of systemic platinum-based chemotherapy in patients with UTUCs.

56 Platinum-based chemotherapy induces cellular senescence.

57 Platinum-based chemotherapy is regularly used as part of

58 that a combination of an mTOR inhibitor and platinum-based chemotherapy might be beneficial to patie

59 The effect of treatment with platinum-based chemotherapy on CTGCT risk was assessed u

60 or 1 who had received at least two previous platinum-based chemotherapy regimens and responded to th

61 hibitors, such as FK866, in conjunction with platinum-based chemotherapy represents a promising thera

62 Adjuvant platinum-based chemotherapy should be considered a new s

63 Treatment with platinum-based chemotherapy shows a dose-dependent inver

64 The standard-of-care treatment for EOC is platinum-based chemotherapy such as cisplatin.

65 l that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum

66 ieving at least stable disease on first-line platinum-based chemotherapy were enrolled.

67 a PARP inhibitor trial and 5 were receiving platinum-based chemotherapy with a plan to receive PARP

68 complete or partial response to first-line, platinum-based chemotherapy with high-grade serous or en

69 currence more than 6 months after first-line platinum-based chemotherapy, and an Eastern Cooperative

70 ung cancer, had previously been treated with platinum-based chemotherapy, and had an Eastern Cooperat

71 toxicity is one of the major side-effects of platinum-based chemotherapy, in particular cisplatin (ci

72 Platinum-based chemotherapy-induced peripheral neuropath

73 changes in intracellular dynamics caused by platinum-based chemotherapy.

74 tedin in patients with SCLC after failure of platinum-based chemotherapy.

75 carcinoma who receive standard, first-line, platinum-based chemotherapy.

76 economical alternatives for the traditional platinum-based cocatalysts for light-driven hydrogen evo

77 ith non-small-cell lung cancers evaluating a platinum-based doublet with or without the programmed de

78 is end, we first investigated the effects of platinum-based drugs on plasma S1P levels in human cance

79 nd application of a micro-needle implantable platinum-based electrochemical sensor for measuring part

80 oordination environments(12) has resulted in platinum-based nanocrystals that enable very high ORR ac

81 Platinum-based neoadjuvant chemotherapy followed by dela

82 (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS

83 py for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-contain

84 therapy regimens and responded to their last platinum-based regimen were randomly assigned (2:1) to o

85 ed regimen, and best response to most recent platinum-based regimen).

86 gression-free interval following penultimate platinum-based regimen, and best response to most recent

87 Platinum-based therapeutics are used to manage many form

88 Platinum-based therapy is the standard of care in patien

89 e not received a PARPi and have responded to platinum-based therapy regardless of BRCA mutation statu

90 th AEGC to explore whether the efficacy of a platinum-based therapy with fluorouracil, leucovorin, an

91 EOC that has not recurred within 6 months of platinum-based therapy, who have not received a PARPi an

92 olizumab/carboplatin/paclitaxel/bevacizumab, platinum-based two-drug combination chemotherapy, or non

93 ed two-drug combination chemotherapy, or non-platinum-based two-drug therapy.

94 The array consists of 4,096 platinum-black electrodes with nanoscale roughness fabri

95 s a rapid start-up, low-cost (no membrane or platinum catalyst), and high volumetric power density sy

96 e is markedly better than that of commercial platinum catalyst, with an overpotential of only -12 mV

97 materials are leading candidates to replace platinum catalysts for the oxygen reduction reaction (OR

98 ployed to study this behavior over supported platinum catalysts.

99 inistration approved and provide benefits of platinum chains with the additional advantages of allowi

100 cer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP inhibitors (PARPi).

101 able strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previou

102 nucleotide excision repair and DNA damage in platinum chemotherapy resistance by profiling DNA damage

103 urs (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant.

104 Gemcitabine-platinum combination chemotherapy initiated within 90 da

105 lock (L) for metal complexes and a dinuclear platinum complex (Pt(2) L) for super-resolution imaging.

106 (FPX) and the substitution-inert polynuclear platinum complex TriplatinNC show significant modulation

107 al-mediated bond-cleavage reaction that uses platinum complexes [K(2)PtCl(4) or Cisplatin (CisPt)] fo

108 ble reaction that expands the application of platinum complexes beyond those in catalysis and cancer

109 However, it is always challenging to design platinum complexes suitable for such research.

110 supramolecular polymer containing zerovalent platinum complexes to form nanoparticles in situ.

111 process that triggers the reactivity of the platinum complexes.

112 Platinum compounds have activity in triple-negative brea

113 s effect was not related to the abundance of platinum compounds in the cochlea, rather cisplatin had

114 mitigating cellular DNA damage formation by platinum compounds.

115 s treated with aminoglycoside antibiotics or platinum-containing chemotherapy agents.

116 h standard chemotherapy after progression on platinum-containing chemotherapy.

117 vorin, and oxaliplatin (FOLFOX) versus a non-platinum-containing regimen of irinotecan and docetaxel

118 Knockdown of FZD7 improved sensitivity to platinum, decreased spheroid formation, and delayed tumo

119 osed loop recycling is considered, the gross platinum demand from the glass industry would be the lar

120 [OR, 2.9, P=0.041], certain chemotherapies [platinum derivatives; OR, 3.0, P=0.034], and a history o

121 elopment of high performance and durable non-platinum direct methanol fuel cell.

122 Platinum disk electrodes of different diameters and NaCl

123 We show that platinum displays a self-adjusting surface that is activ

124 ds and Results We pooled 1863 women from the PLATINUM Diversity (n=1057 women) and PROMUS ELEMENT PLU

125 particles, such as copper, silver, gold, and platinum, do not have the effects observed in the case o

126 risk, a relationship between CTGCT risk and platinum dose has not previously been assessed.

127 The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if th

128 d the optimal protocol for administration of platinum-doublet chemotherapy in a palliative setting.

129 2 signaling, and conferred resistance to the platinum drug cisplatin.

130 insight into a novel approach for design of platinum drugs (and coordination compounds in general) w

131 It is of great significance to track the platinum drugs in real time with super-resolution to elu

132 ovides a new way to improve the targeting of platinum drugs.

133 We find that anisotropic corrosion of the platinum electrode takes place in different stages.

134 xhibits an excellent Ohmic contact to bottom platinum electrode with record-low contact resistance (~

135 receiver, a rectifier circuit, and a pair of platinum electrodes (overall size is 9 x 3 x 2 mm(3)).

136 In this study, platinum electrodes were fabricated on the bio-based pol

137 obilisation of the nanoMIP on screen printed platinum electrodes.

138 using impedance spectroscopy measurements on platinum electrodes.

139 zumab is a new standard treatment option for platinum-eligible recurrent ovarian cancer.

140 icant improvement in overall survival versus platinum-etoposide (hazard ratio [HR] 0.82 [95% CI 0.68-

141 ained improvement in overall survival versus platinum-etoposide (HR 0.75 [95% CI 0.62-0.91]; nominal

142 icant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stag

143 tremelimumab plus platinum-etoposide versus platinum-etoposide alone.

144 side, durvalumab plus platinum-etoposide, or platinum-etoposide alone.

145 or durvalumab plus platinum-etoposide versus platinum-etoposide and for durvalumab plus tremelimumab

146 e results support the use of durvalumab plus platinum-etoposide as a new standard of care for the fir

147 ustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to d

148 addition of tremelimumab to durvalumab plus platinum-etoposide did not significantly improve outcome

149 etoposide group received up to six cycles of platinum-etoposide every 3 weeks and optional prophylact

150 ]), six (2%) patients in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, h

151 nts in the durvalumab plus tremelimumab plus platinum-etoposide group (death, febrile neutropenia, an

152 and sepsis [n=1 each]), and two (1%) in the platinum-etoposide group (pancytopenia and thrombocytope

153 Patients in the platinum-etoposide group received up to six cycles of pl

154 e group, and 88 [33%] of 266 patients in the platinum-etoposide group) and anaemia (34 [13%], 24 [9%]

155 nts in the durvalumab plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in th

156 nts in the durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the durvalumab plu

157 [24%] of 265 patients in the durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients i

158 oside group, 85 (32%) in the durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-e

159 latinum-etoposide group, and 97 (36%) in the platinum-etoposide group.

160 tremelimumab plus platinum-etoposide versus platinum-etoposide in the intention-to-treat population.

161 immunotherapy groups received four cycles of platinum-etoposide plus durvalumab 1500 mg with or witho

162 Durvalumab plus platinum-etoposide showed sustained improvement in overa

163 First-line durvalumab plus platinum-etoposide showed sustained overall survival imp

164 vival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.

165 ts were overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide and for dur

166 de and for durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide in the inte

167 Durvalumab plus tremelimumab plus platinum-etoposide was not associated with a significant

168 poside with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in

169 rvalumab plus platinum-etoposide, and 269 to platinum-etoposide).

170 ed (268 to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus platinum-etop

171 s platinum-etoposide, 268 to durvalumab plus platinum-etoposide, and 269 to platinum-etoposide).

172 ntravenous durvalumab plus tremelimumab plus platinum-etoposide, durvalumab plus platinum-etoposide,

173 mab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone.

174 id not significantly improve outcomes versus platinum-etoposide.

175 measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months.

176 teractive Web Response System, stratified by platinum-free interval, and with a permuted block size o

177 Patients were stratified by platinum-free interval, residual tumour, previous antian

178 ing a vial immunosensor, artificial nanozyme platinum/gold core-shell nanoparticles (Pt@Au NPs) as a

179 was made with either a stainless steel or a platinum grid separated from the sensor by a porous sepa

180 atients in the pembrolizumab plus pemetrexed-platinum group and 180 (90%) of 200 in the placebo plus

181 atients in the pembrolizumab plus pemetrexed-platinum group and 200 (99%) of 202 patients in the plac

182 ve an NO reduction in excess of 2X that of a platinum group metal (PGM) three way catalytic converter

183 Achieving a functional and durable non-platinum group metal-based methanol oxidation catalyst i

184 of simultaneously highly active and durable platinum group metal-free (PGM-free) catalysts and elect

185 electrocatalysts, mostly based on expensive platinum group metals.

186 (90%) of 200 in the placebo plus pemetrexed-platinum group were compliant with QLQ-C30; at week 12,

187 es (M-N-C, M=Fe, Co, Ni, Mn) are the popular platinum group-metal (PGM)-free catalysts for many elect

188 To offset the environmental impact of platinum-group element (PGE) mining, recycling technique

189 ted concentrations of iridium (Ir) and other platinum-group elements (PGE) have been reported in both

190 lly important metals like nickel, copper and platinum-group elements.

191 In contrast, platinum-group metals have been the cornerstone of many

192 hieving optimized oxygen binding strength on platinum-group metals in the presence of hydroxide.

193 am proton exchange membrane (PEM) fuel cell, platinum-group-metal (PGM)-based catalysts account for ~

194 to not reached) with placebo plus pemetrexed-platinum (hazard ratio 0.81 [95% CI 0.60-1.09], p=0.16).

195 oxaliplatin, SN38 and 1,2-diaminocyclohexane-platinum (II), DACHPt.

196 Platinum(II) complexes bearing terpyridyl (tpy) and thio

197 es for the preparation of highly luminescent platinum(ii) cyclometallated pincer complexes are outlin

198 mplies that the presence of Cu(I) center and platinum(II) significantly enhance the bacterium-binding

199 c corrosion of a spherical single crystal of platinum in an aqueous alkaline electrolyte, to map out

200 onjugate in mice and show that the amount of platinum in the brain after treatment with the conjugate

201 artial response over placebo plus pemetrexed-platinum in the KEYNOTE-189 study.

202 d by a bottom mirror surface, e.g., silicon, platinum, is physically constrained to a region defined

203 Here, we introduce conjugation between platinum(IV) prodrugs of cisplatin and perfluoroaryl pep

204 R,2 R-diamine)( rac-2-(2-propynyl)octanoato)platinum(IV) showed higher tumor mass Pt accumulation th

205 e arising from spin-charge conversion in the platinum layer depends on the chirality of the dynamical

206 ined with both pembrolizumab plus pemetrexed-platinum (least-squares mean change: 1.0 point [95% CI -

207 aintained with pembrolizumab plus pemetrexed-platinum (least-squares mean change: 1.3 points [95% CI

208 Pembrolizumab plus pemetrexed-platinum led to superior overall survival and progressio

209 nsferable heterostructured electrocatalysts, platinum/lithium cobalt oxide (Pt/LiCoO(2) ) composites

210 ntribution of novel materials, such as gold, platinum, metal alloys/adatom, graphene, composites and

211 The advantages of using carbon fiber or platinum microelectrodes are because they are promising

212 ated Ag(+) in the extracellular medium using platinum microelectrodes, as a function of cellular expo

213 tion studies, conducted electrochemically at platinum microelectrodes, revealed almost 50% of the Ag-

214 all three components of the Pt(IV) prodrugs (platinum moiety and axial ligands) contribute to the kil

215 olved the structures of individual colloidal platinum nanocrystals by developing atomic-resolution 3D

216 intrinsic heterogeneity of ligand-protected platinum nanocrystals in solution, including structural

217 tial parameters for an oxidation reaction on platinum nanoparticles (NPs) confined in hydrophilic and

218 uced to measure aflatoxin M1 (AFM1) by using platinum nanoparticles (PtNPs) decorated on a glassy car

219 a biosensor device based on graphite oxide, platinum nanoparticles and biomaterials obtained from Bo

220 we exploit the enzyme-mimetic properties of platinum nanoparticles combined with hydroxyl radical pr

221 ti-CRP-rGO(reduced graphene oxide)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to th

222 High YDB concentrations of iridium, platinum, nickel, and cobalt suggest mixing of melted lo

223 -alloyed multicomponent nanoparticles (e.g., platinum-nickel cobalt (Pt-NiCo)).

224 experiments compared with the electron-rich platinum on CeO(2) (100), and a factor of two higher pai

225 Reducing gold rather than platinum onto the mAb-AuNP sandwich enables scanometric

226 oting the reduction and deposition of either platinum or gold onto its surface, generating correspond

227 omplexes of precious metals such as iridium, platinum, or ruthenium still playing a significant role.

228 on deficiency, cosegregates with response to platinum (P < .001) and PARP inhibitor therapy (P < .001

229 mordenite) and a gamma-alumina binder, with platinum particles controllably deposited either on the

230 yield of desired isomers than catalysts with platinum particles inside the zeolite crystals.

231 heptane demonstrates that the catalysts with platinum particles on the binder, which separates platin

232 Platinum particles within the zeolite crystals impose pr

233 High cost platinum (Pt) catalysts limit the application of microbi

234 emonstrated that co-depositing iron (Fe) and platinum (Pt) followed by one single annealing step, wit

235 ged as appealing alternatives to noble-metal platinum (Pt) for catalyzing the oxygen reduction reacti

236 pplying electricity to the adhesive, while a platinum (Pt) wire served as the counter electrode.

237 ns (e.g., propane) by surface oxygenation of platinum (Pt)-alloyed multicomponent nanoparticles (e.g.

238 Despite the importance of platinum [Pt(II)] agents in cancer therapy, accumulating

239 We produced a platinum-quality genome assembly of S. viridis and de no

240 Chemical synthesis of platinum-rare earth metal (Pt-RE) nanoalloys, one of the

241 ncer Intergroup CA125 response despite being platinum refractory and PARP inhibitor resistant.

242 ement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma.

243 Prior PARPi, platinum-refractory disease, or progression on more than

244 ctivity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with

245 of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma.

246 revious line of platinum-based chemotherapy (platinum-refractory).

247 rted to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma.

248 Super-resolution and immunogold platinum replica electron microscopy revealed dynamin al

249 correlative superresolution fluorescence and platinum replica electron microscopy.

250 nsitivity to platinum chemotherapy, ~10% are platinum resistant.

251 escribing dynamics of platinum-sensitive and platinum-resistant cancer cells and interactions reflect

252 lled women (aged >=18 years) with recurrent, platinum-resistant high-grade serous ovarian cancer (det

253 efit of adding berzosertib to gemcitabine in platinum-resistant high-grade serous ovarian cancer.

254 nsitivity to PARPi-ATRi in diverse PARPi and platinum-resistant models, including BRCA1/2 reversion a

255 Platinum-resistant oral cancer has a dismal outcome with

256 re than one line of cytotoxic therapy in the platinum-resistant setting.

257 er analysis in 40 tumours from 26 cases with platinum-resistant TGCT, and combine this with published

258 ectro-oxidation of iodide at polycrystalline platinum-reveals unique (i.e., structure-dependent) patt

259 ted MMAE was also decaged in the presence of platinum salts for extracellular drug release in cancer

260 e partially activated by nontoxic amounts of platinum salts.

261 f 122 upper eyelids of 117 patients received platinum segment chains (mean weight, 1.2 +/- 0.2 g; ran

262 s of a 5-year series of individually sutured platinum segment chains for upper eyelid loading.

263 Platinum segments are an ideal first-line loading implan

264 Platinum segments are US Food and Drug Administration ap

265 Platinum segments of 0.4 and 0.2 g were assembled to cre

266 fferential equations, describing dynamics of platinum-sensitive and platinum-resistant cancer cells a

267 clinical trials as a maintenance therapy in platinum-sensitive ovarian cancer and gastric cancer.

268 d previous lines of cytotoxic therapy in the platinum-sensitive setting but no more than one line of

269 ial, patients aged 18 years or older who had platinum-sensitive, high-grade serous or endometrioid ov

270 Patients with platinum-sensitive, recurrent ovarian carcinoma were ran

271 tro and inhibited tumor growth and increased platinum sensitivity in vivo.

272 that intratumoral ERCC1 levels may determine platinum sensitivity.

273 systems, such as the seeded growth of chiral platinum shells on gold nanorods.

274 for the first time a correlation between the platinum signal and the presence of carbon deposits with

275 these activity enhancements with a focus on platinum size reduction, shape control and core Pt elimi

276 particles showing the dissolution of tin and platinum species during electrocatalysis.

277 d by deployment of a 10-zig covered Cheatham platinum stent.

278 primary platinum use and possess the highest platinum stocks in use by 2016; however, when closed loo

279 opment involved the assembly of a nanoporous platinum structure on a screen-printed carbon electrode

280 Tandem catalytic conversion by platinum supported on gamma-alumina converts various pol

281 , beryllium, cadmium, cesium, lead, mercury, platinum, thallium, tin, and uranium), and their associa

282 n is a standard of care for lung cancer, yet platinum therapy rarely results in substantial tumor reg

283 osely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalli

284 s for therapy in DDR-proficient PC and after platinum therapy.

285 nts were refractory to the last administered platinum therapy.

286 data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy

287 reveal a novel therapeutic vulnerability of platinum-tolerant cancer cells and provide new insight i

288 Defining traits of platinum-tolerant cancer cells could expose new treatmen

289 Frizzled-7 marks platinum-tolerant cancer cells harboring stemness featur

290 These results support the existence of a platinum-tolerant cell population with partial cancer st

291 Additionally, platinum-tolerant cells and tumors exhibited expression

292 Platinum-tolerant cells and tumors were enriched in ALDH

293 Here, new markers associated with platinum-tolerant cells and tumors were identified using

294 FZD7(+) platinum-tolerant ovarian cancer cells were more sensiti

295 202 patients in the placebo plus pemetrexed-platinum-treated group completed at least one PRO assess

296 and jewelry uses represent the most primary platinum use and possess the highest platinum stocks in

297 Randomisation was stratified by previous platinum use, history of CNS metastases, and oestrogen a

298 1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-res

299 Increasing the platinum utilization efficiency is the key to the advanc

300 g synthetic IR spectra of carbon monoxide on platinum, we implement multinomial regression via neural